冠状动脉血栓治疗的药物治疗选择:我们今天在哪里?
Mohammed Ejaz Faizur Rahman1,2, Vidun Wedagedera1, William A E Parker1,2
1Cardiovascular Research Unit, Division of Clinical Medicine, School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
Expert opinion on pharmacotherapy
|January 4, 2025
概括
优化冠状动脉栓塞的抗血栓治疗需要了解药物机制和病理生理学. 本综述指导临床医生个性化治疗,以获得冠状动脉疾病患者更好的治疗结果.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 血栓形成研究研究
背景情况:
- 冠状动脉血栓形成的药物治疗已经进步,改善了患者的治疗结果,但增加了治疗的复杂性.
- 穿皮冠状动脉干预和支架设计已经减少了血栓性并发症,这对临床试验构成了挑战.
- 了解冠状动脉血栓的病理生理学和抗血栓药物机制对于有效的治疗决策至关重要.
研究的目的:
- 审查冠状动脉血栓的病理生理学和相关药物的作用机制.
- 提供关于抗血栓治疗决策问题的概述.
- 为临床医生指导个性化风险管理,并解决证据差距.
主要方法:
- 冠状动脉血栓症病理生理学的文献综述.
- 对抗血栓性药物机制和临床试验数据的分析.
- 对当前药物治疗策略和证据的批判性评估.
主要成果:
- 个人化抗血栓治疗是优化风险管理的关键.
- 评估了可用的抗血栓药物和组合药物的优点和局限性.
- 在药物治疗的证据库中发现了差距.
结论:
- 临床医生需要了解药物特征和病理生理学,以便做出明智的决定.
- 个性化抗血栓治疗方案对于治疗冠状动脉血栓症至关重要.
- 需要进一步的研究来改善冠状动脉血栓治疗和预防的药物治疗.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
465
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
465
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
135
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
135
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
452
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
452
Antianginal Drugs: Nitrates and β-Blockers
517
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
517
Anticoagulant Drugs: Low-Molecular-Weight Heparins
607
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
607


